Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs22.08 B24.66 B24.77 B21.51 B22.87 B23.68 B24.6 BRecherche et développement12.16 B14.71 B14.6 B483 M1.84 B109 M14.97 BRésultat d'exploitation14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BTotal des produits hors exploitation-3 B-672 M-1.71 B-5.74 B-3.58 B8.01 B547 MCharges d'intérêts, nettes des intérêts capitalisés201 M183 M276 M772 M755 M971 M1.04 BRésultat hors exploitation, hors charges d'intérêts-299 M-366 M-114 M123 M363 M-169 M-86 MRevenus/dépenses exceptionnels-2.9 B-489 M-1.87 B-6.63 B-4.69 B7.21 B-406 MRésultat avant impôts16.5 B22.78 B21.73 B15.06 B16.69 B32.58 B24.94 BPart des actionnaires dans le résultat———————Impôts1.78 B1.9 B3.78 B1.74 B2.62 B5.78 B3.9 BIntérêts ne donnant pas le contrôle / intérêts minoritaires———————Autres produits/charges après impôts———————Résultat net avant activités abandonnées14.71 B20.88 B17.94 B13.33 B14.07 B26.8 B21.04 BActivités abandonnées———21.83 B00—Résultat net14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BAjustement de dilution———————Dividendes privilégiés———————Résultat net dilué revenant aux actionnaires ordinaires14.71 B20.88 B17.94 B35.15 B14.07 B26.8 B21.04 BBénéfice par action de base (BPA de base)5.597.936.8313.885.8411.138.73Bénéfice par action dilué (BPA dilué)5.517.816.7313.725.7911.038.63Nombre moyen d'actions de base en circulation2.63 B2.63 B2.63 B2.53 B2.41 B2.41 B—Nombre d'actions en circulation après dilution2.67 B2.67 B2.66 B2.56 B2.43 B2.43 B—EBITDA21.9 B25.95 B25.3 B37.91 B38.83 B42.62 B21.03 BEBIT14.67 B18.65 B18.37 B30.43 B31.49 B35.12 B16.9 BCoût des ventes28.43 B29.86 B31.09 B26.55 B27.47 B30.26 B31 BAutres coûts des ventes———————Amortissements (flux de trésorerie)7.23 B7.39 B6.97 B7.49 B7.34 B7.5 B7.74 B
Johnson & Johnson Common Stock
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey.
The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments.
The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000.